// App-Quantinova.ai

4321 : Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial

Researchers

Presenter

  • G Chi

Principal Investigators

  • C M Gibson

  • A F Hernandez

  • R D Hull

  • A T Cohen

  • R A Harrington

  • F Alkhalfan

  • A Kalayci

  • M Kerneis

  • T Nafee

Medical Centers

  • Beth Israel Deaconess Medical Center - Boston - United States of America

  • Duke Clinical Research Institute - Durham - United States of America

  • Guy's Hospital, London, United Kingdom

  • Stanford University Medical Center - Stanford - United States of America

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • N/A

Biomarkers

  • Apurinic/Apyrimidinic Endodeoxyribonuclease 1

Drug/Treatment

  • betrixaban

  • Enoxaparin

  • Enoxaparin sodium

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Portola Pharmaceuticals

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved